

# SCAAR

Real-life clinical outcomes with the use of Orsiro in Sweden: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

## Conclusions

- In this large, nationwide, retrospective analysis Orsiro<sup>®</sup> is associated with a significantly lower risk of Target Lesion Revascularization (TLR) compared to other modern n-DES\*.
- Orsiro shows numerically lower rates of In-Stent Restenosis (ISR) and definite Stent Thrombosis (ST) compared to other modern n-DES.
- These results emphasize the potential incremental clinical benefits of Orsiro's ultrathin strut during Percutaneous Coronary Intervention (PCI).


## Study design

Nationwide, retrospective, multicentre, observational registry recording all PCI procedures in Sweden between 2011-2017.

## Endpoints

### Clinical endpoints

- All-cause Death, Myocardial Infarction (MI), Definite ST, ISR, TLR by PCI out to 2 years




Patient characteristics <sup>1</sup>	Orsiro n = 4,561	n-DES n = 69,570	SMD**
Age years, (SD)‡	67.2 ± 11.1	67.8 ± 10.9	0.049
Male	74.1%	73.7%	0.008
Diabetes	22.1%	21.4%	0.018
Hypertension	62.9%	61.5%	0.029
Previous MI	22.1%	21.0%	0.027
Previous PCI	17.1%	17.8%	0.019
<b>Clinical indication</b>			
Stable CAD	20.4%	20.8%	0.049
Unstable CAD	9.7%	9.9%	0.049
NSTEMI	38.7%	39.7%	0.049
STEMI	28.5%	26.6%	0.049


Lesion characteristics <sup>1</sup>	Orsiro n = 4,561	n-DES n = 69,570	SMD
B2/C	65.6%	61.6%	0.084
Bifurcation	19.0%	18.7%	0.008
3VD/LM	20.3%	23.1%	0.067

\* n-DES: Xience Family, Resolute Family, Promus Family, Synergy, and Ultimaster > 1000 implantations;  
 \*\* SMD: Standardized Mean Difference, value >0.1 may indicate statistically significant differences.<sup>2</sup>  
 ‡ Data shown as mean ± SD


## TLR rate by PCI out to 2 years<sup>1</sup>



## ISR rate out to 2 years<sup>1</sup>



## Definite ST rate out to 2 years<sup>1</sup>



## Clinical outcomes out to 2 years<sup>1</sup>

Clinical Endpoint	Adjusted HR (95% CI)	p-value
	Orsiro vs. n-DES	
TLR	0.75 [0.60-0.94]	0.013
All-cause Death	0.99 [0.72-1.35]	0.94
MI	1.19 [0.99-1.43]	0.06
ISR	0.81 [0.63-1.03]	0.09
DST	0.90 [0.55-1.46]	0.66

1. Sergio B et al. Real-life clinical outcomes with the use of an ultrathin sirolimus-eluting stent in Sweden: A report from the Swedish coronary angiography and angioplasty registry; Presented at EuroPCR 2019; May, 2019; 2. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics-Simulation and Computation. 2009 May 14;38(6):1228-34.

Clinical data conducted with Orsiro, Orsiro Mission's predecessor device can be used to illustrate Orsiro Mission clinical outcomes.

Orsiro is a trademark or registered trademark of the BIOTRONIK Group of Companies. Xience is a trademark of Abbott Cardiovascular Systems Inc.; Resolute and Integrity are registered trademarks of Medtronic Vascular Inc.; PROMUS and PROMUS PREMIER are trademarks or registered trademarks of the Boston Scientific Group of Companies; Synergy is a registered trademark of Boston Scientific. Ultimaster is a trademark or registered trademark of the Terumo Group of companies.